1-(2-甲基-4-吡啶)哌嗪 | 98010-38-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(2-甲基-4-吡啶)哌嗪
• 英文名称: 1-(2-methylpyridin-4-yl)piperazine
• 英文别名: 1-(2-methyl-4-pyridinyl)piperazine；1-(2-methylpyrid-4-yl)piperazine
• CAS: 98010-38-9
• 化学式: C₁₀H₁₅N₃
• 分子量: 177.249
• InChiKey: FIPQSNSVDULSJM-UHFFFAOYSA-N

物化性质

• 沸点：
  335.1±37.0 °C(Predicted)
• 密度：
  1.059±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  28.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1-(2-甲基-4-吡啶)哌嗪 、 叔丁氧羰基-D-叔亮氨酸 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 13.25h， 以90%的产率得到tert-butyl ((1R)-2,2-dimethyl-1-((4-(2-methyl-4-pyridinyl)-1-piperazinyl)carbonyl)propyl)carbamate
  参考文献：
  名称：

  EP1695961

  摘要：

  公开号：
• 作为产物：
  描述：

  4-溴-2-甲基吡啶 在 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 三氟乙酸 、 bis(dibenzylideneacetone)-palladium⁽⁰⁾ 、 sodium t-butanolate 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 17.0h， 生成 1-(2-甲基-4-吡啶)哌嗪
  参考文献：
  名称：

  Wnt信号通路抑制剂及其应用

  摘要：

  本发明涉及一种具有Wnt信号通路抑制活性的杂环化合物，包括该化合物及其药学上可接受的盐、各种同位素、各种异构体或各种晶型结构，具有通式I所示的结构：本发明所涉及的化合物及其联合应用组合物可以有效抑制Wnt信号通路，能够用于治疗或预防与Wnt信号通路相关的病症。

  公开号：

  CN104876912B

文献信息

• [EN] OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'OGA
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2021123291A1

  公开（公告）日：2021-06-24

  The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations; or alpha synucleinopathies, in particular Parkinson's disease, dementia due to Parkinson's (or neurocognitive disorder due to Parkinson's disease), dementia with Lewy bodies, multiple system atrophy, or alpha synucleinopathy caused by Gaucher's disease.

  本发明涉及O-GlcNAc水解酶（OGA）抑制剂。该发明还涉及包含这类化合物的药物组合物，制备这类化合物和组合物的方法，以及利用这类化合物和组合物预防和治疗抑制OGA有益的疾病的用途，例如tau病变，特别是阿尔茨海默病或进行性上行性核瘫痪；以及伴有tau病理的神经退行性疾病，特别是由C9ORF72突变引起的肌萎缩侧索硬化或额颞叶痴呆；或α-突触核蛋白病，特别是帕金森病、帕金森病引起的痴呆（或由帕金森病引起的神经认知障碍）、带有Lewy小体的痴呆、多系统萎缩，或由高雪氏病引起的α-突触核蛋白病。
• Piperazinyl-substituted pyridine and imidazole anti-arrhythmic agents
  申请人：Pfizer, Inc.

  公开号：US04806536A1

  公开（公告）日：1989-02-21

  A series of novel 4-substituted piperazinyl-pyridine and 4-substituted piperazinyl-imidazole compounds have been prepared, including their pharmaceutically acceptable salts, wherein the 4-substituent is a lower phenylalkyl group or a derivative thereof further substituted on the phenyl moiety by a sulphamoyl or sulphonylamino group or by a nitro, amino or acetamido group. These particular compounds are useful in therapy as highly effective anti-arrhythmic agents and therefore, are of value in the treatment of various cardiac arrythmias. The most preferred member compound of the series is N-4-[1-hydroxy-2-(4-[4-pyridinyl]-1-piperazinyl)ethyl]phenyl} methanesulphonamide. Methods for preparing all these compounds from known starting materials are provided.

  一系列新颖的4-取代哌嗪基吡啶和4-取代哌嗪基咪唑化合物已经制备完成，包括它们的药用可接受盐，其中4-取代基是一个较低的苯基烷基或其衍生物，进一步在苯基上被磺酰胺基或磺酰胺氨基团或硝基、氨基或乙酰氨基团取代。这些特定化合物在治疗中具有高效的抗心律失常作用，因此在治疗各种心律失常方面具有价值。该系列中最优选的成员化合物是N-4-[1-羟基-2-(4-[4-吡啶基]-1-哌嗪基)乙基]苯基}甲磺酰胺。提供了从已知起始材料制备所有这些化合物的方法。
• Sulfone derivatives, process for their production and use thereof
  申请人：——

  公开号：US20030187023A1

  公开（公告）日：2003-10-02

  A compound represented by the formula: 1 wherein R is a cyclic hydrocarbon group, or the like; W is a bond, or the like; X is a divalent hydrocarbon group, or the like; Y and Z are each independently —N(R 6 )— or the like; ring A is a nitrogen-containing heterocyclic ring, or the like; R5 and R6 are independently hydrogen atom, a hydrocarbon group, or the like; Z′ is imidoyl group, or the like; a is 0, 1 or 2; and b is 0 or 1, or a salt thereof.

  一个由以下式表示的化合物： 其中R是一个环烃基团，或类似物；W是一个键，或类似物；X是一个二价碳氢基团，或类似物；Y和Z分别独立地为—N(R6)—或类似物；环A是一个含氮杂环环，或类似物；R5和R6独立地为氢原子、一个碳氢基团，或类似物；Z′是亚胺基团，或类似物；a为0、1或2；b为0或1，或其盐。
• [EN] PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS<br/>[FR] DÉRIVÉS DE PYRIMIDINE UTILISÉS EN TANT QU'INHIBITEURS DE KINASE, ET LEURS APPLICATIONS THÉRAPEUTIQUES
  申请人：NANTBIOSCIENCE INC

  公开号：WO2016138527A1

  公开（公告）日：2016-09-01

  The present invention provides kinase inhibitors with anti-proliferative activity comprising substituted pyrimidine derivatives and pharmaceutically-acceptable formulations thereof. In addition, the invention provides methods for making novel compounds and methods for using the compounds.

  本发明提供了具有抗增殖活性的激酶抑制剂，包括取代嘧啶衍生物及其药用可接受的配方。此外，本发明提供了制备新化合物的方法以及使用这些化合物的方法。
• 4-Methyl-7-Amino/Amido Coumarin Derivatives as Potential Antimicrobials and Antioxidants
  作者：Muthipeedika Nibin Joy、Yadav D. Bodke、Sandeep Telkar

  DOI：10.1007/s10600-020-03106-y

  日期：2020.7

  An array of previously synthesized 4-methyl-7-amino and amido coumarins 4a–u has been screened for their antimicrobial and antioxidant properties. Some of the compounds exhibited promising antibacterial and antifungal activities (MIC ranging from 4–64 μg/mL) when compared to the respective standards. Compound 4u showed comparable antibacterial activity with the standard, ciprofloxacin, whereas compounds 4u and 4t displayed promising antifungal activity when compared to the standard, fluconazole. The in silico docking studies against gyrase enzyme revealed the fact that 4u possessed hydrogen bonding and significant hydrophobic interactions, which may be the reason for its superior antibacterial activity as compared to the other compounds. Compounds 4c and 4m showed comparable antioxidant activity with the standard, BHT, which can be attributed to the presence of electron-donating substituents.

  一批先前合成的4-甲基-7-氨基和酰胺香豆素4a–u已被筛选其抗菌和抗氧化性能。与各自的标准相比，一些化合物表现出有前景的抗菌和抗真菌活性（MIC范围为4-64 μg/mL）。化合物4u显示出与标准环丙沙星相当的抗菌活性，而化合物4u和4t在与标准氟康唑相比时显示出有前景的抗真菌活性。针对拓扑异构酶的计算对接研究揭示了4u具有氢键和显著的疏水相互作用，这可能是其相对于其他化合物具有更优越抗菌活性的原因。化合物4c和4m显示出与标准BHT相当的抗氧化活性，这可以归因于存在供电子取代基。